For research and educational purposes only. Not medical advice.
Efinopegdutide Reference
Educational, not medical advice reference for Efinopegdutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also k…
Reference summary
Phase 2 NASH data have been published; pepSmart displays efinopegdutide only as trial-context educational content.
- Categories
- GLP-1, Fat Loss
- Aliases
- MK-6024, HM12525A, GLP-1/glucagon dual agonist
- Evidence posture
- human — Human Phase 2 trial data exist, but efinopegdutide remains investigational — no FDA-approved drug label.
- Regulatory status
- Investigational. Efinopegdutide is a GLP-1 / glucagon dual receptor agonist licensed by Merck from Hanmi Pharmaceutical with Phase 2 programs in NASH. There is no FDA-approved drug label.
- Content review status
- investigational verified